An initial investigation by the UK Competition and Markets Authority (CMA) has found UnitedHealth’s £1.2bn deal to buy EMIS could reduce competition, leading to worse outcomes for the NHS and ultimately patients and UK…
Continue Reading
In todays fast-paced world, it is easy to miss out on important information, especially if you are trying to keep up with a lot of different sources. That is where the daily digest comes in – it is a tool that compiles all the posts created on the previous day, providing you with a convenient summary of everything that happened so you can stay informed, educated, and engaged with the Digital Health world around you.
Continue Reading
Prescription digital therapeutics company Pear Therapeutics is exploring “strategic alternatives,” including a possible company sale, merger or acquisition. In a press release, the company said it hired a financial advisor to look into actions that…
Continue Reading
Adaptimmune and TCR2 Therapeutics, two clinical-stage biotechs that have recently cut staff to conserve capital, are coming together in a deal that aligns their cell therapy strategies. The business combination also extends the new…
Continue Reading
Talaris Therapeutics aimed to transform solid organ transplants with a cell therapy that replaces anti-rejection drugs patients need for the rest of their lives. But after clinical trial setbacks, the biotech has decided to end two kidney transplant studies. Although a separate test of its experimental therapy is continuing in a rare autoimmune condition, Talaris has commenced a restructuring plan that it said could culminate in a merger or sale of the company.
The restructuring announced Thursday will lead to the layoff of about one-third of Talaris’s staff. As of the end of the third quarter of 2022, the Louisville, Kentucky-based biotech…
